Annual CFI
-$155.24 M
-$411.70 M-160.53%
31 December 2023
Summary:
Iovance Biotherapeutics annual cash flow from investing activities is currently -$155.24 million, with the most recent change of -$411.70 million (-160.53%) on 31 December 2023. During the last 3 years, it has risen by +$162.61 million (+51.16%). IOVA annual CFI is now -160.53% below its all-time high of $256.45 million, reached on 31 December 2022.IOVA Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$48.80 M
-$89.02 M-221.34%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly cash flow from investing activities is currently -$48.80 million, with the most recent change of -$89.02 million (-221.34%) on 30 September 2024. Over the past year, it has increased by +$30.21 million (+38.24%). IOVA quarterly CFI is now -131.81% below its all-time high of $153.40 million, reached on 31 March 2023.IOVA Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$192.93 M
+$30.21 M+13.54%
30 September 2024
Summary:
Iovance Biotherapeutics TTM cash flow from investing activities is currently -$192.93 million, with the most recent change of +$30.21 million (+13.54%) on 30 September 2024. Over the past year, it has dropped by -$111.00 million (-135.47%). IOVA TTM CFI is now -159.30% below its all-time high of $325.33 million, reached on 30 September 2022.IOVA TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -160.5% | +38.2% | -135.5% |
| 3 y3 years | +51.2% | -482.8% | -1745.7% |
| 5 y5 years | +59.8% | -1496.3% | -34.8% |
IOVA Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -160.5% | +51.2% | -131.8% | +68.9% | -159.3% | +54.1% |
| 5 y | 5 years | -160.5% | +59.8% | -131.8% | +88.5% | -159.3% | +54.1% |
| alltime | all time | -160.5% | +59.8% | -131.8% | +88.5% | -159.3% | +54.1% |
Iovance Biotherapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$48.80 M(-221.3%) | -$192.93 M(-13.5%) |
| June 2024 | - | $40.22 M(-136.1%) | -$223.15 M(-46.9%) |
| Mar 2024 | - | -$111.51 M(+53.1%) | -$420.14 M(+170.6%) |
| Dec 2023 | -$155.24 M(-160.5%) | -$72.84 M(-7.8%) | -$155.24 M(+89.5%) |
| Sept 2023 | - | -$79.01 M(-49.6%) | -$81.94 M(-215.7%) |
| June 2023 | - | -$156.78 M(-202.2%) | $70.79 M(-78.1%) |
| Mar 2023 | - | $153.40 M(>+9900.0%) | $323.33 M(+26.1%) |
| Dec 2022 | $256.45 M(>+9900.0%) | $461.00 K(-99.4%) | $256.45 M(-21.2%) |
| Sept 2022 | - | $73.72 M(-23.0%) | $325.33 M(+23.1%) |
| June 2022 | - | $95.76 M(+10.7%) | $264.37 M(+2701.4%) |
| Mar 2022 | - | $86.52 M(+24.8%) | $9.44 M(+7049.2%) |
| Dec 2021 | $132.00 K(-100.0%) | $69.34 M(+443.9%) | $132.00 K(-101.3%) |
| Sept 2021 | - | $12.75 M(-108.0%) | -$10.45 M(-86.3%) |
| June 2021 | - | -$159.16 M(-306.1%) | -$76.16 M(-77.7%) |
| Mar 2021 | - | $77.21 M(+31.4%) | -$340.75 M(+7.2%) |
| Dec 2020 | -$317.85 M(-453.1%) | $58.75 M(-210.9%) | -$317.85 M(-9.1%) |
| Sept 2020 | - | -$52.95 M(-87.5%) | -$349.79 M(+19.2%) |
| June 2020 | - | -$423.76 M(-523.3%) | -$293.34 M(-255.1%) |
| Mar 2020 | - | $100.11 M(+273.3%) | $189.10 M(+110.0%) |
| Dec 2019 | $90.03 M(-123.3%) | $26.81 M(+667.2%) | $90.03 M(-162.9%) |
| Sept 2019 | - | $3.50 M(-94.0%) | -$143.17 M(-51.6%) |
| June 2019 | - | $58.68 M(+5580.8%) | -$296.04 M(-23.2%) |
| Mar 2019 | - | $1.03 M(-100.5%) | -$385.22 M(-0.3%) |
| Dec 2018 | -$386.28 M(-758.3%) | -$206.38 M(+38.2%) | -$386.28 M(+114.8%) |
| Sept 2018 | - | -$149.37 M(+389.7%) | -$179.84 M(+1025.5%) |
| June 2018 | - | -$30.50 M(>+9900.0%) | -$15.98 M(-140.1%) |
| Mar 2018 | - | -$22.00 K(-137.9%) | $39.85 M(-32.1%) |
| Dec 2017 | $58.68 M(+559.7%) | $58.00 K(-99.6%) | $58.68 M(-30.5%) |
| Sept 2017 | - | $14.49 M(-42.8%) | $84.38 M(+57.6%) |
| June 2017 | - | $25.33 M(+34.7%) | $53.54 M(+200.5%) |
| Mar 2017 | - | $18.80 M(-27.0%) | $17.82 M(+100.3%) |
| Dec 2016 | $8.89 M | $25.77 M(-257.5%) | $8.89 M(-214.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2016 | - | -$16.36 M(+57.3%) | -$7.75 M(-126.8%) |
| June 2016 | - | -$10.39 M(-205.2%) | $28.95 M(-147.8%) |
| Mar 2016 | - | $9.88 M(+8.3%) | -$60.55 M(-15.0%) |
| Dec 2015 | -$71.21 M(+4372.9%) | $9.12 M(-55.2%) | -$71.21 M(-12.9%) |
| Sept 2015 | - | $20.35 M(-120.4%) | -$81.75 M(-20.1%) |
| June 2015 | - | -$99.89 M(>+9900.0%) | -$102.26 M(+4213.8%) |
| Mar 2015 | - | -$782.00 K(-45.1%) | -$2.37 M(+48.9%) |
| Dec 2014 | -$1.59 M(>+9900.0%) | -$1.43 M(+783.4%) | -$1.59 M(+851.6%) |
| Sept 2014 | - | -$161.30 K(+6913.0%) | -$167.30 K(+794.7%) |
| June 2014 | - | -$2300.00(-32.4%) | -$18.70 K(+14.0%) |
| Mar 2014 | - | -$3400.00(+1033.3%) | -$16.40 K(+26.2%) |
| Dec 2013 | -$13.00 K(<-9900.0%) | -$300.00(-97.6%) | -$13.00 K(+2.4%) |
| Sept 2013 | - | -$12.70 K(<-9900.0%) | -$12.70 K(<-9900.0%) |
| June 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2012 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2012 | - | $0.00(0.0%) | -$60.70 K(+327.5%) |
| June 2012 | - | $0.00(0.0%) | -$14.20 K(-54.3%) |
| Mar 2012 | - | $0.00(-100.0%) | -$31.10 K(-61.7%) |
| Dec 2011 | -$81.10 K(<-9900.0%) | -$60.70 K(-230.5%) | -$81.10 K(+366.1%) |
| Sept 2011 | - | $46.50 K(-375.1%) | -$17.40 K(-72.8%) |
| June 2011 | - | -$16.90 K(-66.2%) | -$63.90 K(+30.1%) |
| Mar 2011 | - | -$50.00 K(-1766.7%) | -$49.10 K(<-9900.0%) |
| Dec 2010 | $0.00(0.0%) | $3000.00(>+9900.0%) | $0.00(-100.0%) |
| Sept 2010 | - | $0.00(-100.0%) | -$3000.00(0.0%) |
| June 2010 | - | -$2100.00(+133.3%) | -$3000.00(+233.3%) |
| Mar 2010 | - | -$900.00(<-9900.0%) | -$900.00(<-9900.0%) |
| Dec 2009 | $0.00 | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2009 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2009 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2009 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2008 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2008 | - | $0.00 | $0.00 |
FAQ
- What is Iovance Biotherapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual CFI year-on-year change?
- What is Iovance Biotherapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly CFI year-on-year change?
- What is Iovance Biotherapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics TTM CFI year-on-year change?
What is Iovance Biotherapeutics annual cash flow from investing activities?
The current annual CFI of IOVA is -$155.24 M
What is the all time high annual CFI for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual cash flow from investing activities is $256.45 M
What is Iovance Biotherapeutics annual CFI year-on-year change?
Over the past year, IOVA annual cash flow from investing activities has changed by -$411.70 M (-160.53%)
What is Iovance Biotherapeutics quarterly cash flow from investing activities?
The current quarterly CFI of IOVA is -$48.80 M
What is the all time high quarterly CFI for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly cash flow from investing activities is $153.40 M
What is Iovance Biotherapeutics quarterly CFI year-on-year change?
Over the past year, IOVA quarterly cash flow from investing activities has changed by +$30.21 M (+38.24%)
What is Iovance Biotherapeutics TTM cash flow from investing activities?
The current TTM CFI of IOVA is -$192.93 M
What is the all time high TTM CFI for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high TTM cash flow from investing activities is $325.33 M
What is Iovance Biotherapeutics TTM CFI year-on-year change?
Over the past year, IOVA TTM cash flow from investing activities has changed by -$111.00 M (-135.47%)